Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Cancer Discov. 2015 Oct 2;5(12):1271–1281. doi: 10.1158/2159-8290.CD-15-0748

Fig. 3. Combined inhibition of co-amplified RTKs is required for response.

Fig. 3

(A) OE33 cells were treated with the indicated concentrations of crizotinib alone, lapatinib alone, or both drugs in combination for 72h, and cell titer was determined. (B) Western blot of OE33 cells treated with the indicated concentrations of crizotinib, lapatinib, or both drugs in combination for 24h. (C) SNU638 cells exogenously expressing HER2, MET, or empty vector control were treated with the indicated concentrations of drug(s) for 72h, and cell titer was determined. (D) The same cells from (C) were treated with the indicated concentrations of drug for 24h, and western blotting was performed with the indicated antibodies. (E) FISH images showing >25-fold amplification of both MET and HER2 in the same tumor cells from Patient #3. (F) PET images from Patient #3 obtained pre-treatment and after 2 months of therapy with combined MET/HER2 inhibition.